PrabotulinumtoxinA-xvfs (Jeuveau, Evolus) for the Temporary Treatment of Glabellar Lines: What Does This Toxin Bring to the Table?
By Missy Clifton, MD Jeuveau (prabotulinumtoxinA-xvfs, Evolus, Inc.) received approval from the U.S. Food and Drug Administration (FDA) on February 1, 2019, for the temporary improvement in the appearance of moderate-to-severe glabellar lines. PrabotulinumtoxinA (PBoNT/A) is a proprietary 900-kDa purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate-to-severe glabellar […]